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Abstract: 
Background: With the increased frequency of diagnostic imaging, pancreatic cysts are now 
detected in >3% of American adults. Most of these are intraductal papillary mucinous neoplasm 
(IPMN) with well-established but variable malignant potential. A biomarker that predicts 
malignant potential or dysplastic grade would help determine which IPMN require removal or 
can be safely observed. We previously reported that pancreatic fluid prostaglandin E2 (PGE2) 
levels may have promise as a predictor of IPMN dysplasia and seek to validate these results in 
the current study. 
 
Study Design: Pancreatic cyst/duct fluid was prospectively collected from 100 patients with 
IPMN undergoing pancreatic resection. Surgical pathology revealed 47 low/moderate grade, 34 
high grade, and 20 invasive IPMN. PGE2 levels were assessed by enzyme-linked immunoassay 
and correlated with IPMN dysplasia grade, demographics, clinical radiologic/pathologic 
variables, acute/chronic pancreatitis and non-steroidal anti-inflammatory drug use. 
 
Results: Mean pancreatic cyst fluid PGE2 levels in high grade and invasive IPMN were 
significantly higher than low/moderate grade IPMN (3.5 and 4.4 respectively versus 1.2pg/µl, 
p<0.0016). At a threshold of 1.1pg/µl, PGE2 was 63% sensitive, 79% specific, and 71% accurate 
for detection of high grade/invasive IPMN. When tested in the subset of IPMN patients with 
preoperative pancreatic cyst fluid CEA >192ng/mL, PGE2 at a threshold of 0.5pg/µl 
demonstrated 78% sensitivity and 100% specificity, and 86% accuracy for detection of high 
grade/invasive IPMN.  
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Conclusions: Our results validate pancreatic cyst fluid PGE2 as an indicator of IPMN dysplasia 
especially in select patients with preoperative pancreatic cyst fluid CEA >192ng/mL. The 
inclusion of PGE2/CEA in a diagnostic biomarker panel may facilitate more optimal treatment 
stratification of IPMN patients. 
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Prostaglandin E2; IPMN; Dysplasia; Biomarker; Pancreatic cyst, CEA 
 
Abbreviations: 
IPMN: intraductal papillary mucinous neoplasm 
MCN: mucinous cystic neoplasm 
PGE2: prostaglandin E2 
COX-2: cyclooxygenase-2 
NSAID: non-steroidal anti-inflammatory medications 
CEA: carcinoembryonic antigen 
LGD: low grade dysplasia 
MGD: moderate grade dysplasia 
HGD: high grade dysplasia 
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Introduction: 
Pancreatic cancer will be diagnosed in an estimated 53,070 Americans this year. In 2016, 
41,780 died from pancreatic cancer. This makes pancreatic cancer the third leading cause of 
cancer-related death in the United States surpassing mortality from breast cancer(1). The 
aggressive biology and typical late discovery of pancreatic cancer contribute to these 
statistics(1). Most patients have inoperable disease and no chance for cure at the time of 
presentation(2). Thus, there is an urgent need for both improved systemic treatment options and 
earlier diagnostic strategies. Early detection and prevention of pancreatic cancer may be the 
answer for a unique subset of high-risk patients. Cystic lesions of the pancreas, some of which 
may progress to pancreatic cancer, provide the clinician with an opportunity to intervene prior to 
malignant transformation. While non-discriminatory resection of all pancreatic cysts would 
prevent many cancer cases, an unacceptable number of patients with low malignant potential 
pancreatic cysts would undergo unnecessary, potentially morbid pancreatic resection. Accurate 
preoperative diagnosis of pancreatic cyst type and malignant potential is therefore of utmost 
importance for optimal surgical risk stratification. 
 
Intraductal papillary mucinous neoplasm (IPMN) is the most common premalignant 
mucinous cystic lesion of the pancreas. Most IPMN are accurately diagnosed based on 
radiographic features of multifocal ductal dilation alone. Unifocal (solitary) IPMN, however, 
must be distinguished from mucinous cystic neoplasm (MCN). MCN may be diagnosed by the 
presence of ovarian stroma on core biopsy or EUS-directed micro forceps biopsy. Unifocal 
IPMN may be diagnosed by the presence of a GNAS mutation. If neither are present, the patient 
falls into a category of the undifferentiated solitary mucinous cystic lesion of the pancreas (3). 
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Clinical management of IPMN, once diagnosed, is guided by an assessment of malignant 
potential. A fine needle aspiration consistent with high grade atypia or a core biopsy or EUS-
directed micro-forceps biopsy consistent with high grade dysplastic or invasive IPMN may 
occasionally be available. An accurate dysplastic grade, however, is usually not known prior to 
IPMN surgical resection. Malignant potential of IPMN is linked to type of pancreatic ductal 
involvement. IPMN with branch-duct involvement alone (branch type) may often be observed 
while IPMN with main-duct involvement (with or without branch-duct involvement, i.e., mixed 
type and main type) are usually recommended for resection due to a higher risk of malignant 
transformation(4). Preoperative differentiation of IPMN ductal involvement is guided by cross-
sectional imaging and endoscopic modalities. Nearly 30% of IPMN cases, however, are 
misclassified as having main duct involvement preoperatively that do not on surgical pathology 
(5). Conversely, 20% of IPMN thought to have branch-duct involvement alone preoperatively 
have main duct involvement on surgical pathology (5). 
 
Although branch duct versus main duct differentiation is an important distinction in 
assessing IPMN malignant risk, it is unreliable by itself. There are a number of clinical factors 
and imaging characteristics which may be useful in prediction of IPMN malignant potential, 
including age, symptoms/signs/conditions, imaging, cytology, DNA profiling, labs, family 
history, obesity(6), smoking(7), new onset diabetes(8), main duct size, and presence of mural 
nodules(4). However, no existing preoperative predictive factors are accurate enough to identify 
high-risk IPMN for surgical removal and/or low-risk IPMN that can be safely monitored. Highly 
accurate preoperative biomarkers are necessary to optimize preoperative risk stratification. 
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 Prostaglandin E2 (PGE2) is a product of cyclooxygenase-2 (COX-2), a key enzyme in the 
inflammatory pathway(9). COX-2 overexpression and elevated PGE2 levels have been observed 
in multiple cancer types including pancreas(10-13). We previously reported that pancreatic cyst 
fluid PGE2 levels correlated with degree of IPMN dysplasia in a small cohort of IPMN patients 
(n=29)(14). In the present study, we aim to validate these findings with a larger cohort to 
evaluate the diagnostic utility of PGE2 as a biomarker for high risk IPMN. 
 
Methods: 
 Pancreatic cyst fluid or main duct fluid (in the case of isolated main duct IPMN) samples 
were obtained from IPMN patients at the time of endoscopic ultrasound guided fine needle 
aspiration and/or pancreatic resection at Indiana University Health University Hospital between 
June 2003 and August 2016. All patients provided informed consent in accordance with the 
Indiana University Institutional Review Board. Additional de-identified pancreatic fluid samples 
(n=10) were kindly provided by Johns Hopkins School of Medicine (Dr. Michael Goggins) 
under a material transfer agreement between Indiana University and Johns Hopkins University. 
After procurement, pancreatic cyst fluid aliquots were placed immediately on ice and then stored 
at -80o C. All pancreatic cyst fluid samples were from patients with diagnoses of IPMN. The 
diagnosis of IPMN was confirmed on surgical pathology by a University Hospital Staff 
pathologist and then reconfirmed by a pancreatic pathologist. Pathologic parameters including 
IPMN dimensions, main/branch duct involvement, and dysplasia grade (according to World 
Health Organization criteria) were assessed. A retrospective review of our prospectively 
collected database which records demographic and clinical data for these patients was also 
performed. This was supplemented through review of electronic (and paper) medical records. For 
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this study, patients taking oral hypoglycemic medications and/or insulin at the time of 
preoperative evaluation were categorized as diabetic. Patients taking non-steroidal anti-
inflammatory medications (NSAIDs) at the time of pre-operative evaluation were categorized as 
NSAID users. 
 
PGE2 and CEA Analysis 
Pancreatic cyst fluid (15-50 µl) PGE2 was analyzed using a PGE2 enzyme-linked 
immunosorbent assay (ELISA) (GE Healthcare Bio-Sciences Corp, Cranbury, NJ). In this assay, 
unlabeled PGE2 within pancreatic fluid samples competes with a fixed amount of peroxidase-
labeled PGE2 for binding to a plate-bound, PGE2-specific antibody. With the addition of a 
substrate, bound PGE2 peroxidase is quantified and converted to PGE2 concentration in the 
samples (pg/ul). Carcinoembryonic antigen (CEA) was determined by a Beckman Coulter DxI 
800 analyzer or ELISA (Sigma-Aldrich, St. Louis, O). All patient samples underwent PGE2 
analysis. A subset (n=63) had adequate fluid for concomitant CEA analysis. 
 
Statistical Analysis 
 IBM Statistical Package for the Social Sciences (SPSS) 24 was used for all statistical 
analyses. Graphpad Prism 7.02 was used for graphical representation of data. Descriptive 
statistics including mean, standard deviation, and frequencies were calculated as appropriate. 
Baseline demographic and clinic-pathologic data were compared between low/moderate grade 
dysplasia (LGD/MGD) and high-grade dysplasia (HGD)/invasive IPMN using t test for 
continuous data and chi square for categorical data. Groups were further subdivided into 
LGD/MGD, HGD, and invasive IPMN and compared using ANOVA and chi square. Pearson 
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correlation coefficient was calculated for determination of PGE2 association with other 
continuous variables. PGE2 was then analyzed based on each additional categorical 
demographic/clinicopathologic variable using t test and ANOVA. Univariate and multivariate 
analyses were conducted to compare PGE2 levels between IPMN dysplasia grades. P-values of 
<0.05 were considered statistically significant. The diagnostic utility of PGE2 as a biomarker for 
HGD/invasive IPMN was ascertained using sensitivity/specificity calculations and receiver 
operator characteristic analyses. 
 
Results: 
A cohort of 100 patients preoperatively diagnosed with IPMN consented to participation 
in the study. Following pancreatic resection and subsequent pathological confirmation of IPMN, 
this cohort was classified by dysplastic grade into 47 with low/moderate grade (LGD/MGD), 34 
with high grade (HGD), and 20 with invasive IPMN. Age and gender were not significantly 
different between grades of IPMN dysplasia. Among patients with LGD/MGD, HGD, and 
invasive IPMN, 39.1%, 55.2%, and 42.9% respectively were men (p=0.4). Mean age of 
LGD/MGD IPMN patients was 68.8 years compared to 65.5 and 70.1 years for those with HGD 
and invasive IPMN (p=0.3). Prevalence of diabetes and NSAID use did not vary according to 
degree of dysplasia. Although there was no difference in the rate of clinically diagnosed 
pancreatitis between individual dysplastic grades, the HGD/invasive combined IPMN cohort 
which is considered to be of higher risk was more commonly associated with pathologic 
diagnosis of chronic pancreatitis than lower risk LGD/MGD IPMN (82.1% vs. 61.4%, p=0.05). 
Consistent with published literature, the rate of main duct involvement was higher in 
HGD/invasive versus low/moderate grade IPMN (79.1% vs. 44.4%, p=0.001). 
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 The concentration of PGE2 was determined in patient pancreatic cyst fluid and correlated 
with grade of IPMN dysplasia (Figure 1). Mean pancreatic cyst fluid PGE2 levels in LGD/MGD, 
HGD, and invasive IPMNs were significantly different, increasing in stepwise fashion from 
1.2±2.7 to 3.5±3.7 and 4.4±5.1 pg/µl, respectively (p=0.002 for LGD/MGD vs. either HGD or 
invasive). Similarly, upon comparison of low-risk LGD/MGD versus high-risk HGD/invasive 
IPMN groups, the significant increase in PGE2 with dysplasia persisted (1.2±2.7 vs. 3.7±4.1 
pg/µl, p<0.001). Pancreatic cyst fluid PGE2 levels were not affected by demographic or clinical 
variables such as gender, age, procedure used to obtain pancreatic fluid, presence of diabetes or 
pancreatitis, NSAID use, main or branch duct involvement, or cyst size (Table 1). Following 
multivariable analysis, including PGE2, duct involvement, and pathologic pancreatitis, only 
PGE2 and duct involvement demonstrated independently significant differences between IPMN 
grades of dysplasia. 
The diagnostic utility of PGE2 as a biomarker of IPMN dysplasia was assessed. Using 
Youden’s index, a PGE2 threshold of >1.1 pg/µl was chosen to indicate a positive test for 
HGD/invasive IPMN. This threshold yielded a sensitivity of 63.0% and specificity of 78.7% for 
detecting HGD/invasive IPMN, with a positive likelihood ratio of 3.0. The receiver operator 
curve revealed an area under the curve (AUC) of 0.77 (Figure 2). PGE2 was then evaluated in 
only those patients with likely pre-operative mucinous cyst diagnosis based on cyst fluid CEA of 
>192 ng/mL (n=35). Within this subset of patients, mean PGE2 in LGD/MGD IPMN was very 
low at 0.1±0.03 pg/µl, increasing to 3.4±1.1 and 4.2±1.7 pg/µl for HGD and invasive IPMN 
respectively (p=0.03) (Figure 3A) When comparing only two groups: LGD/MGD (0.1±0.03 
pg/µl) and HGD/invasive (3.8±0.09 pg/µl) IPMN, this difference remains (p=0.001) (Figure 
3B). At a threshold of 0.5 pg/µl chosen using Youden’s index, PGE2 more accurately diagnosed 
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high-risk HGD/invasive IPMN with 78% sensitivity, 100% specificity, 86% accuracy, and an 
AUC of 0.91. 
To compare PGE2 performance with the ability of EUS-directed fine needle 
aspiration/cytology to detect high grade atypia, 81 of the 100 IPMN study patients with cytologic 
analysis of pancreatic cyst fluid were identified. Of these, 53% were either non-diagnostic for 
high grade/malignant cells (n=16) or incorrect diagnoses (n=27) upon final surgical pathology. 
After excluding patients with non-diagnostic cytology results, sensitivity was 23%, specificity 
was 89%, and accuracy was 58% for the identification of high grade/invasive IPMN by cytology 
(n=65). In the cytology cohort with cyst fluid CEA >192 ng/mL (n=27), sensitivity, specificity, 
and accuracy were 38%, 73%, and 52% respectively. 
Discussion: 
 For patients with pancreatic IPMN, an accurate assessment of malignant potential is 
critical to guide optimal clinical care. The gold standard for determination of malignant potential 
is dysplastic grade assessed on pathology. Few IPMN are feasible for core biopsy or EUS-
directed micro-forceps biopsy with adequate sampling for dysplastic grade assessment. In the 
current series, no core biopsies were performed. EUS-directed fine-needle-aspiration is routine in 
larger IPMN but the resultant cytology is often inaccurate or non-diagnostic for IPMN dysplasia 
(53% in the current series). Other markers of malignant potential including demographic, 
clinical, laboratory, endoscopic, and radiographic parameters fall short of an accurate prediction 
of dysplastic grade. Thus, a significant challenge persists in preoperative determination of IPMN 
dysplastic grade. Due to the lack of reliable indicators of IPMN dysplasia, patients may be 
inappropriately risk stratified and either forego necessary or undergo unnecessary surgical 
resection. This may result in under-treatment of high-risk IPMN or over-treatment of low-risk 
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IPMN, respectively. Thus, accurate biomarkers of IPMN dysplasia are needed for optimal 
clinical management. 
 Newer pancreatic cyst fluid biomarkers are more commonly sufficient to distinguish cyst 
types. None, however, has consistently been a reliable indicator of IPMN dysplasia(15). Perhaps 
the most widely used pancreatic cyst fluid biomarker is CEA(16). CEA is able to differentiate 
mucinous from non-mucinous type cysts with an accuracy of 77% according to a large multi-
institutional validation study of 1,861 patients(17). However, CEA alone lacks sufficient 
accuracy for routine identification of mucinous cysts and does not correlate with grade of 
dysplasia(18-20). A DNA mutation in KRAS is sufficient to diagnose mucinous cystic lesions 
(IPMN and MCN). A GNAS mutation is sufficient to diagnose IPMN and distinguish it from 
MCN and other non-mucinous pancreatic cyst types(21, 22). Neither the presence of KRAS, 
GNAS, or both mutations predict malignancy(18, 23). PancraGEN is a commercially available 
test that measures quantity and quality of DNA, KRAS, and GNAS oncogene mutations, LOH 
tumor suppressor mutations and DNA mutation copy number. Based on a proprietary 
combination of this molecular data and clinical variables, PancraGEN categorizes a pancreatic 
cyst as benign, statistically indolent, statistically higher risk, or aggressive(24). These categories 
guide a clinician’s recommendations for surveillance or surgery. This test is expensive but 
reports a higher accuracy than the 2012 algorithm as put forward by the revised International 
Consensus Guidelines. It too falls short of an optimal test to predict malignant potential. 
We previously reported that pancreatic fluid prostaglandin E2 (PGE2) may be a promising 
biomarker of IPMN dysplasia(14). The present study seeks to validate this in a larger cohort of 
100 IPMN patients, 53 with HGD or invasive IPMN. Pancreatic cyst fluid PGE2 levels were 
significantly higher in HGD/invasive IPMN compared to LGD/MGD. PGE2 alone demonstrated 
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70.8% accuracy in the detection of high-risk IPMN, compared to cytologic cyst fluid analysis 
with an accuracy of 58%. No correlation was found between PGE2 levels and the presence of 
chronic inflammation (chronic pancreatitis) other than pancreatitis associated with HGD or 
invasive IPMN. Similarly, pancreatic fluid PGE2 levels did not correlate with NSAID use. 
Importantly, when evaluated in a population of patients with CEA >192ng/mL, the accepted cut-
off for mucinous versus non-mucinous cyst differentiation, diagnostic accuracy increased to 86% 
with 78% sensitivity and 100% specificity. This demonstrates that when utilized in a subset of 
patients with higher CEA production, the diagnostic accuracy of PGE2 as a biomarker of IPMN 
dysplasia substantially improves. Why a higher CEA would identify a subset of IPMN patients 
where PGE2, a marker of inflammation, would be more predictive is unclear. Finally, while cyst 
fluid PGE2 levels in other pancreatic cysts such serous cystadenomas (SCN) and MCN are low as 
in LGD/MGD IPMNs, PGE2 levels in a small number of pseudocysts tested in our laboratory 
were relatively high (unpublished observations). Thus, PGE2 would be most useful specifically 
in patients with pre-operative diagnosis of IPMN as a predictor of IPMN dysplasia. 
The observed stepwise increase in mean PGE2 levels with IPMN dysplastic grade 
suggests that PGE2 production may be associated with malignant progression. To further 
evaluate this, a prospective study testing serial samples from individual patients under 
surveillance for possible IPMN should be performed. PGE2 is known to be involved in both 
angiogenesis and immunosuppression in the tumor microenvironment thus facilitating 
tumorigenesis(25). We have previously shown that the PGE2 pathway plays an important role in 
pancreatic tumorigenesis. Specifically, we demonstrated that COX-2, one of the enzymes that 
catalyzes the reaction producing prostaglandins, is over-expressed in precursor lesions known as 
pancreatic intraepithelial neoplasias (PanINs) and pancreatic adenocarcinomas(10, 11). 
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Furthermore, NSAIDs that inhibit COX activity and block the inflammatory response may 
inhibit tumor growth in combination with other agents both in cell culture and animal models, 
including developmental models, of pancreatic cancer(10, 26-28). 
Limitations of the current study include being retrospective with the majority of samples 
originating from a single institution. Validation of these results in a large, prospective multi-
institution study would be optimal. Additionally, all patients included in this study underwent 
surgical resection and therefore may not be representative of the population overall population of 
surveillance and surgical patients in whom PGE2 testing would potentially be useful. 
 Other potential cyst fluid biomarkers for the determination of IPMN dysplasia have been 
reported in the literature. The cytokine interleukin-1β (IL1β) was shown to be 92% accurate in 
detecting HGD/invasive IPMN in a sample size of 40 cyst fluids(29). This report of IL1 and 
ours of PGE2, both markers of inflammation elevated in high-risk IMPN, provide evidence for 
the involvement of inflammation with malignant progression – either as a cause or consequence. 
Regardless, such immune response indicators may serve as potential biomarkers of dysplasia and 
warrant further testing. Telomerase activity has also been recently reported to be higher in 
invasive than non-invasive mucinous lesions with an accuracy of 88.2% in the identification of 
HGD/invasive IPMN(30, 31). Several microRNA (miRNA)-based biomarkers have shown 
promise in detecting high-risk IPMN(32, 33). Matthaei et al. reported a panel of several miRNAs 
with a sensitivity and specificity of 89% and 100% for differentiating HGD from LGD 
IPMN(34). Mucins, specifically, MUC2 and MUC4 were elevated in pancreatic cyst fluid of 
HGD/invasive IPMN as compared to LGD/MGD IPMN in a study by Maker et al. (35). A later 
publication reported 89.7% accuracy of a panel of mucins for detecting HGD and invasive IPMN 
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(36). One or more of these markers may fulfill the clinical need for a marker of IPMN dysplasia, 
but all await more extensive validation. 
 
Conclusions 
We have validated PGE2 as a promising pancreatic fluid biomarker able to distinguish 
low/moderate grade from high/invasive grade IPMN. Pending future prospective evaluation, 
such a biomarker would optimize clinical management of pancreatic cyst patients. In patients 
suspected of IPMN, a diagnostic panel including pancreatic fluid PGE2 may facilitate risk 
stratification by identifying high-risk (high/invasive grade) lesions for surgical resection and 
low-risk (low/moderate grade) lesions appropriate for monitoring. 
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Table 1. Correlation of PGE2 Concentration with Demographics and Clinicopathologic 
Variables 
 
Mean PGE2 
concentration 
p Value 
Sex 
 
0.6 
Male 2.7  
Female 2.3  
Age* -0.2 0.1 
Procedure 
 
0.1 
Operating room 2.7  
Endoscopic 1.7  
Clinical AP/CP  0.9 
Yes 2.5  
No 2.9  
Pathologic CP  0.4 
Yes 2.8  
No 2.7  
DM  0.7 
Yes 2.8  
No 2.4  
NSAID use  0.8 
Yes 2.3  
No 2.6  
Duct involvement  0.6 
BD 2.2  
MD involved 2.7  
Cyst size* -0.2 0.1 
*Continuous data analyzed with Pearson Correlation Coefficient. 
AP, acute pancreatitis; CP, chronic pancreatitis; DM, diabetes mellitus. 
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FIGURE LEGENDS 
Figure 1. Prostaglandin E2 (PGE2) concentration in intraductal papillary mucinous neoplasm 
(IPNM) pancreatic fluid. PGE2 is plotted (y-axis) for each pancreatic cyst categorized by grade 
of IPMN dyplasia (x-axis). Mean PGE2 values are shown for each dysplasia grade with the 
middle horizontal lines. These are bordered by standard error of the mean bars. Mean PGE2 
increases in a stepwise fashion from LGD/MGD, HGD, and invasive IPMN. This difference is 
statistically significant. LGD/MGD, low/moderate-grade dysplasia; HGD, high-grade dysplasia. 
 
intraductal papillary mucinous neoplasm (IPNM) dysplasia. Pancreatic cyst fluid prostaglandin 
E2 
 
Figure 2. Receiver operator characteristic (ROC) curve analysis of prostaglandin E2 (PGE2) for 
the diagnosis of HGD/invasive intraductal papillary mucinous neoplasm (IPMN). ROC curve 
shown here demonstrates high rate of diagnostic accuracy of PGE2 for diagnosis of high-grade 
dysplasia and invasive IPMN. 
 
Figure 3. Pancreatic fluid prostaglandin E2 (PGE2) concentration in patients with cyst fluid CEA 
> 192 ng/mL. Pancreatic cyst fluid PGE2 is plotted (y-axis) for each grade of intraductal 
papillary mucinous neoplasm (IPMN) dysplasia (x-axis) in only those with preoperative 
pancreatic cyst fluid CEA >192 ng/mL. (A) Divides IPMN dysplasia grade into 3 groups, 
LGD/MGD, HGD, and invasive IPMN. Mean PGE2 values again increase in a stepwise fashion 
with increasing dysplasia grade. (B) Divides IPMN dysplasia into only two groups, LGD/MGD 
and HGD/invasive IPMN. The same significant difference between LGD/MGD and 
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HGD/invasive IPMN is demonstrated. LGD/MGD, low/moderate-grade dysplasia; HGD, high-
grade dysplasia. 
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Precis 
Pancreatic cyst fluid was collected from 100 patients with varying grades of intraductal papillary 
mucinous neoplasm (IPNM) dysplasia. Pancreatic cyst fluid prostaglandin E2 levels increased in 
a step-wise fashion with increasing grade of IPMN dysplasia and may therefore serve as a useful 
biomarker for the detection of high-risk IPMN. 
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